Key result
Beta-blockers linked to ~63% lower death or transplant risk in HF with Chagas cardiomyopathy.
Why the study?
Does beta-blocker therapy improve survival in patients with Chagas cardiomyopathy?
Population
456 patients with heart failure from the REMADHE trial, including 68 (14.9%) with Chagas cardiomyopathy
Comparison
Beta-blocker therapy vs No beta-blocker therapy
Design
Cohort
Authors
Loading...
Beta-blockers were associated with better survival in Chagas HF; leaves open whether randomized trials will confirm benefit.
Cohort (n=456)
Does beta-blocker therapy improve survival in patients with Chagas cardiomyopathy?
Hazard Ratio: 0.37 (95% CI 0.14–0.97)
p-value: p=0.044
Beta-blocker therapy is associated with significantly improved survival in patients with heart failure due to Chagas cardiomyopathy.
Issa et al. (2009) conducted a cohort in Heart failure and Chagas cardiomyopathy (n=456). Beta-blocker therapy vs. No beta-blocker therapy was evaluated on All-cause mortality or heart transplantation (HR 0.37, 95% CI 0.14-0.97, p=0.044). Beta-blocker therapy was associated with improved survival in patients with heart failure and Chagas cardiomyopathy (HR 0.37; 95% CI 0.14-0.97; P=0.044).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: